Skip to main content
Update Location

My Location

Update your location to show providers, locations, and services closest to you.

Enter a zip code
Select a campus/region

Ali Ataya, MD

Critical Care Medicine Specialist, Pulmonologist (Lung Specialist)

Photo of Ali Ataya

About me

My name is Dr. Ataya, and I am an associate professor of medicine in the University of Florida Division of Pulmonary, Critical Care & Sleep Medicine, director of the Pulmonary Hypertension Program and the HHT and Rare Lung Disease Program. I specialize in pulmonary disease, critical care medicine and internal medicine with clinical interest in pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH), hereditary hemorrhagic telangiectasia (HHT), lymphangioleiomyomatosis (LAM), pulmonary alveolar proteinosis (PAP) and other rare lung disorders.

My training started at the Royal College of Surgeons in Ireland (RCSI), where I earned my medical degree. I completed my internal medicine residency at the Cleveland Clinic in Ohio. Eventually, I completed my specialty training in pulmonary & critical care medicine here at UF in 2016. I am board certified by the American Board of Critical Care Medicine, American Board of Pulmonary Medicine and the American Board of Internal Medicine.

I maintain a membership of various medical professional societies, including the American Thoracic Society (ATS), America College of Chest Physicians (ACCP) and Pulmonary Hypertension Association (PHA). In addition, I am a strong patient advocate and am actively involved in various patient foundations.

I am involved in various clinical trials in the fields of pulmonary hypertension, intensive care medicine and rare pulmonary diseases.

My locations

Active clinical trials


160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim or placebo for 48 weeks. Subjects completing the 48 week placebo-controlled period will receive…

Ali Ataya
Accepting Candidates
18 Years - N/A
ROR-PH-303 (APD811-303)

Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.

Ali Ataya
Accepting Candidates
18 Years - N/A
View all of Dr. Ataya's active clinical trials

My research

Top areas of exploration

  • Dyspnea , 10 publications
  • Pulmonary Embolism , 4 publications
  • Lung Diseases , 4 publications
  • Pleural Effusion , 4 publications

Research activity

104 publications

281 citations

Why is this important?
View more of Ali Ataya's research activity

Search our accepted insurances list

Please note: Some physicians and practices might not accept a specific insurance plan. Our list is also subject to change, and sometimes that change is not yet reflected in this list. Please contact the practice to confirm that your insurance is accepted. A representative will be happy to assist you.

See all

My areas of focus

Stories and news

View more stories related to Ali Ataya